BCR and B-cell chronic lymphocytic leukemia: Furthermore, we propose that bendamustine efficacy could be increased by its combination with the state-of-the-art BCR pathway inhibitors ibrutinib or idelalisib, as both drugs were able to decrease CD69 levels and therefore sensitize CLL cells to bendamustine.